<i>LRP5</i> -related primary osteoporosis: phenotypic spectrum and treatment response to zoledronic acid
<i>LRP</i>5-related disorders should be considered in patients with recurrent fractures and visual involvement. Zoledronate appears effective in improving bone density, reducing fracture frequency, and promoting vertebral remodeling, although further studies are required to determine optimal treatment duration.
Authors
- Proteek Sen (ORCID: https://orcid.org/0000-0002-6758-2848)
- Chamila Balagamage
- Nicola Crabtree
- Suma Uday
- Denise Williams
Institutions
- Birmingham Dental Hospital (GB)
- Birmingham Women’s and Children’s NHS Foundation Trust (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1515/jpem-2025-0652
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00